Meta-analysis of genome-wide association studies of Attention-Deficit/Hyperactivity Disorder by Neale, Benjamin M et al.
Meta-Analysis of Genome-Wide 
Association Studies of Attention- 
Deficit/Hyperactivity Disorder 
 
Benjamin M. Neale, Ph.D., Sarah E. Medland, Ph.D., Stephan Ripke, M.D., 
Philip Asherson, M.R.C.Psych., Ph.D., Barbara Franke, Ph.D., Klaus-Peter Lesch, M.D., 
Stephen V. Faraone, Ph.D., Thuy Trang Nguyen, Dipl. Math. oec., 
Helmut Schäfer, Ph.D., Peter Holmans, Ph.D., Mark Daly, Ph.D., 
Hans-Christoph Steinhausen, M.D., Ph.D., D.M.Sc., Christine Freitag, M.D., M.A., 
Andreas Reif, M.D., Tobias J. Renner, M.D., Marcel Romanos, M.D., 
Jasmin Romanos, M.D., Susanne Walitza, M.D., Andreas Warnke, M.D., Ph.D., 
Jobst Meyer, Ph.D., Haukur Palmason, Ph.D., Jan Buitelaar, M.D., 
Alejandro Arias Vasquez, Ph.D., Nanda Lambregts-Rommelse, Ph.D., 
Michael Gill, Mb B.Ch. B.A.O., M.D., M.R.C.Psych., F.T.C.D., Richard J.L. Anney, Ph.D., 
Kate Langely, Ph.D., Michael O’Donovan, F.R.C.Psych., Ph.D., Nigel Williams, Ph.D., 
Michael Owen, Ph.D., F.R.C.Psych., Anita Thapar, M.D., Lindsey Kent, M.D., Ph.D., 
Joseph Sergeant, Ph.D., Herbert Roeyers, M.D., Ph.D., Eric Mick, Sc.D., 
Joseph Biederman, M.D., Alysa Doyle, Ph.D., Susan Smalley, Ph.D., 
Sandra Loo, Ph.D., Hakon Hakonarson, M.D., Ph.D., Josephine Elia, M.D., 
Alexandre Todorov, Ph.D., Ana Miranda, M.D., Fernando Mulas, M.D., Ph.D., 
Richard P. Ebstein, Ph.D., Aribert Rothenberger, M.D., Ph.D., 
Tobias Banaschewski, M.D., Ph.D., Robert D. Oades, Ph.D., 
Edmund Sonuga-Barke, Ph.D., James McGough, M.D., Laura Nisenbaum, Ph.D., 
Frank Middleton, Ph.D., Xiaolan Hu, Ph.D., Stan Nelson, M.D., for the Psychiatric 





Objective: Although twin and family studies have shown attention-deficit/hyperactivity 
disorder (ADHD) to be highly heritable, genetic variants influencing the trait at a genomewide 
significant level have yet to be identified. As prior genome-wide association studies 
(GWAS) have not yielded significant results, we conducted a meta-analysis of existing studies 
to boost statistical power. Method: We used data from four projects: a) the Children’s 
Hospital of Philadelphia (CHOP); b) phase I of the International Multicenter ADHD Genetics 
project (IMAGE); c) phase II of IMAGE (IMAGE II); and d) the Pfizer-funded study from the 
University of California, Los Angeles, Washington University, and Massachusetts General 
Hospital (PUWMa). The final sample size consisted of 2,064 trios, 896 cases, and 2,455 controls. 
For each study, we imputed HapMap single nucleotide polymorphisms, computed association 
test statistics and transformed them to z-scores, and then combined weighted z-scores in a 
meta-analysis. Results: No genome-wide significant associations were found, although an 
analysis of candidate genes suggests that they may be involved in the disorder. Conclusions: 
Given that ADHD is a highly heritable disorder, our negative results suggest that the effects of 
common ADHD risk variants must, individually, be very small or that other types of variants, e.g., 
rare ones, account for much of the disorder’s heritability. J. Am. Acad. Child Adolesc. Psychiatry, 
2010;49(9):884–897. Key Words: ADHD, meta-analysis, association, GWAS, genetics 
 
 
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric phenotypes affecting 
children and adolescents. It is characterized by an inability to focus, high levels of impulsivity and age-
inappropriate hyperactivity, and increased rates of antisocial, anxiety, mood, and substance use disorders. With 
estimates of prevalence ranging from 5% to 12%1,2 and 2% to 5% in adults,3,4 ADHD is a substantial public 
health concern. 
  
Previous work in ADHD has established a strongly heritable component to the phenotype, with genetic factors, 
across 20 twin studies, explaining approximately 76% of the phenotypic variance.5–7 There appears to be 
substantial overlap between the two ADHD symptom dimensions hyperactivity/impulsivity and inattention.8 The 
heritability of ADHD is high, regardless of whether it is measured as a dimensional trait or a categorical disorder. 
Genome-wide linkage and hypothesis-driven candidate gene association studies have failed to unequivocally 
identify specific genetic variation that predisposes to ADHD, although genome-wide levels of significance were 
derived in a meta-analysis for variants within or close to the dopamine D4 (DRD4) and D5 receptor (DRD5) 
genes.9 Similarly, genome-wide association studies (GWAS) of ADHD in children have not yet yielded genome-
wide significant association to common variation. The first genome-wide association scan of 909 trios from the 
International Multicenter ADHD Genetics (IMAGE) study did not find any significant associations,10 although an 
  
analysis of ADHD-related quantitative traits in this data set revealed (trait-specific) genome-wide significance for 
two variants, in the CDH13 gene encoding the neural adhesion protein cadherin 13 and the GFOD1 gene 
encoding a protein of unknown function.11 The other GWAS of childhood ADHD 12,13 did not reveal any 
genome-wide significant associations, nor did a small, pooled GWAS of 343 cases with persistent, adult ADHD 
and 304 controls did not provide statistically significant association findings.14 The recently reported first 
genome-wide study of copy number variants in approximately 400 trios from Children's Hospital of Philadelphia 
likewise did not result in genome-wide significant results.15 
To determine whether a combination of the samples from studies in childhood ADHD would be sufficient to 
identify genes underlying the heritable component of ADHD, we conducted a meta-analysis of these genome-
wide association scans. Although we failed to identify any genome-wide significant association, there is some 
evidence that true associations are present in the top end of our distribution of results. 
 
Method 
Samples   
Our total data set comprises four projects: a) the Children's Hospital of Philadelphia (CHOP); b) phase I of the 
International Multisite ADHD Genetics Project (IMAGE); c) phase II of IMAGE (IMAGE II); and d) the Pfizer-
funded study from the University of California, Los Angeles, Washington University, and Massachusetts General 
Hospital (PUWMa). Each of these datasets has been described elsewhere.10,12,13,15 For this meta-analysis, 
we attempted to include the same individual-level data as those included in the original publication, but amended 
the analysis with additional quality control at the single nucleotide polymorphism (SNP) and individual level to 
maintain quality control through the necessary imputation step (described below). We also restricted the analysis 
to one affected offspring per family (which eliminated three individuals from analysis). In addition, we imputed all 
missing data, so the results from the imputation are fully complete for all individuals, which slightly changed the 
results for each subsample from the published results. 
  
The IMAGE trio samples were collected using a common protocol with centralized training and reliability testing 
of raters and centralized data management. Family members were of white European origin from countries 
including Belgium, Germany, Ireland, the Netherlands, Spain, Switzerland, the United Kingdom, and Israel. At 
the IMAGE sites, parents of children were interviewed with the Parental Account of Childhood Symptom (PACS), 
a semi-structured, standardized, investigator-based interview developed as an instrument to provide an 
objective measure of child behavior. Both parents and teachers completed the respective versions of the 
Conners ADHD rating scales and the Strengths and Difficulties Questionnaire. The assessment procedures 
have been described in more detail elsewhere.16–20 Probands had been referred for assessment of 
hyperactive, disruptive, or disorganized behavior and had been clinically diagnosed with ADHD (or hyperkinetic 
disorder, the most closely equivalent category in the ICD-10 nomenclature used at some of the clinics). Most 
probands (N = 868) met criteria for DSM-IV combined-type ADHD, and additional probands met criteria for 
  
DSM-IV inattentive subtype (N = 13) or hyperactive subtype (N = 33) or missed one of the ADHD diagnoses by a 
single item on the structured interview (N = 19). We retained these latter families because, upon review of the 
medical record and structured interview data, the ADHD diagnosis was confirmed. Exclusion criteria were 
autism, epilepsy, IQ <70, brain disorders, and any genetic or medical disorder associated with externalizing 
behaviors that might mimic ADHD. All data were collected with informed consent of parents and with the 
approval of the site's institutional review board or ethical committee. 
The IMAGE II ADHD samples included some samples from the original IMAGE project along with samples 
provided by colleagues at other sites, using similar but not identical methods. In Germany, families were 
recruited in order of clinical referral in the outpatient clinics in Wuerzburg, Homburg, and Trier. Families were of 
white German ancestry. All cases met DSM-IV criteria for ADHD. The index child was 6 years or more of age, 
further affected siblings were included when at least 6 years of age. All children were assessed by full semi-
structured interview (Kiddie-Sads-PL-German Version or Kinder-DIPS) and parent and teacher ADHD DSM-IV–
based rating scales to ensure pervasiveness of symptoms. Exclusion criteria were IQ <80, comorbid autistic 
disorders or somatic disorders (e.g., hyperthyroidism, epilepsy, neurological diseases, severe head trauma), 
primary affective disorders, Tourette syndrome, psychotic disorders or other severe primary psychiatric 
disorders, and birth weight <2,000 g. 
  
At the Cardiff site, children ages 6 to 16 years of white British ancestry were assessed by interviewing parents 
with the Parent Child and Adolescent Psychiatric Assessment (CAPA), a semi-structured research diagnostic 
interview, and a telephone interview with the teacher using the Child ADHD Teacher Telephone Interview. All 
cases met diagnostic criteria for DSM-IV ADHD or ICD-10 hyperkinetic disorder or DSM-III-R ADHD and had IQ 
test scores >70. Exclusion criteria were pervasive developmental disorder, Tourette syndrome, psychosis or any 
neurological conditions. At the Scottish site, children ages 6 to 16 years, of white British ancestry were assessed 
by interviewing parents with the CAPA. To confirm pervasiveness, teachers completed the Conners Teacher 
Rating Scale. All cases met diagnostic criteria for DSM-IV ADHD. Children with an IQ <70, autistic spectrum 
disorder, head injury, known chromosomal abnormality, encephalitis, or significant medical conditions such as 
epilepsy were excluded. At the Dutch site, assessment data are available for 112 subjects 3 to 18 years of age 
with DSM-IV ADHD and related comorbidities, including mood, anxiety, oppositional defiant disorder (ODD) and 
conduct disorder (CD). Most of the sample was collected as part of a sibling pair genome-wide linkage study in 
ADHD.21 Subjects were assessed using the DSM-IV version of the Diagnostic Interview Schedule for Children 
(DISC-P) with both parents, supplemented by Conners' Questionnaires (old versions), the Childhood Behavior 
Checklist (CBCL), and Teacher Report Form (TRF). In addition, we obtained ADHD symptom severity scores 
from the parents on the Strengths and Weaknesses of ADHD symptoms and Normal behaviors (SWAN) 
questionnaire. 
  
The IMAGE II control samples (2,653 population controls of European ancestry) were collected for an 
institutional review board–approved GWAS of schizophrenia and have been described elsewhere.22 Briefly, the 
  
control participants were drawn from a US nationally representative survey panel (of approximately 60,000 adult 
individuals at any one time, with constant turnover) ascertained via random digit dialing. Participants were 
screened for psychosis and bipolar disorder but not ADHD. Control participants were not screened for ADHD. A 
blood sample was collected via a US national phlebotomy service. Control participants gave written consent for 
their biological materials to be used for medical research at the discretion of the National Institute of Mental 
Health. 
The PUWMa samples were collected independently at three sites using similar but slightly different methods: 
Massachusetts General Hospital (MGH), Washington University, and University of California, Los Angeles 
(UCLA). At MGH, 309 families were recruited from clinics at. Screening and recruitment for some subjects (N = 
121) occurred before publication of DSM-IV. Initial affection status for those subjects was based on DSM-IIIR 
criteria; however lifetime DSM-IV-TR criteria was asked at follow-up, and only those subjects endorsing a life-
time DSM-IV-TR diagnosis of ADHD were enrolled. Remaining subjects were screened and assessed according 
to DSM-IV-TR criteria (N = 188). Psychiatric assessments were made with K-SADSE (Epidemiologic Version). 
Potential probands were excluded if they had major sensorimotor handicaps (deafness, blindness), 
psychosis/schizophrenia, autism, inadequate command of the English language, or a Full Scale IQ <80. At 
Washington University, 272 families were selected from a population-representative sample identified through 
birth records of the state of Missouri, for a genetic epidemiologic study of the prevalence and heritability of 
ADHD. The original sample included 812 complete male and female twin pairs and six individual twins 7 to 19 
years of age at the time of interview identified from the Missouri Family Registry from 1996 to 2002. Families 
were invited into the study if at least one child exhibited three or more inattentive symptoms on a brief screening 
interview. Parents reported on their children and themselves, and the youths on themselves, using the Missouri 
Assessment of Genetics Interview for Children (MAGIC), a semi-structured psychiatric interview. DSM-IV 
diagnoses of ADHD were based on parental reports (most of the time, maternal). Families were excluded if a 
parent/guardian reported mental retardation or if the parent/guardian and twins could not speak English. At 
UCLA, 156 subjects were drawn from 540 children and adolescents 5 to 18 years of age and 519 of their 
parents ascertained from 370 families with ADHD-affected sibling pairs. Lifetime psychiatric diagnoses were 
based on semi-structured diagnostic interviews conducted by master's degree–level clinical psychologists or 
highly trained interviewers with extensive experience and reliability training in psychiatric diagnoses. Children 
and adolescents were assessed using the Schedule for Affective Disorders and Schizophrenia for School-Age 
Children-Present and Lifetime version (K-SADS-PL). Adult parents were assessed using the Schedule for 
Affective Disorders and Schizophrenia–Lifetime version (SADS-LA-IV), supplemented with the K-SADS 
Behavioral Disorders module for diagnosis of ADHD and disruptive behavior disorders. Direct interviews were 
supplemented with parent and teacher versions of the Swanson, Nolan, and Pelham, version IV (SNAP-IV) 
rating scale, as well as a parent-completed CBCL and Teacher Report Form. Parents also completed current 
ratings of self and spouse behavior with the ADHD Rating Scale IV. Subjects were excluded from participation if 
they were positive for any of the following: neurological disorder, head injury resulting in concussion, lifetime 
diagnoses of schizophrenia or autism, or estimated Full Scale IQ < 70. Subjects on stimulant medication were 
  
asked to discontinue use for 24 hours before their visit. 
The CHOP ADHD trio families were recruited from pediatric and behavioral health clinics in the Philadelphia 
area.15 Inclusion criteria included families of European descent with an ADHD proband (6–18 years of age). 
Exclusionary criteria included prematurity (<36 weeks), mental retardation, major medical and neurological 
disorders, pervasive developmental disorder, psychoses, and major mood disorders. Diagnostic data were 
collected using the K-SADS interview. 
 
Table 1 presents the breakdown of samples that were included in the analysis. Three of these samples are 
proband–parent trio-based samples, with the fourth being a case-only sample. To analyze these controls, we 
selected genomically matched, pre-existing controls, available through the genetics data repository of the National 
Institute of Mental Health. The final sample size consisted of 2,064 trios, 896 cases, and 2,455 controls. 






Imputation and Association Analysis 
  
Each of the studies had been conducted on different platforms (Illumina 550K for CHOP, Perlegen 600K for 
IMAGE, Affymetrix 500K for IMAGE II, and Illumina 1M Duo for PUWMa). From these genome-wide association 
datasets, we imputed untyped loci across the genome using the HapMap Phase III European CEU and TSI 
samples as the reference panel.23,24 The IMAGE II sample had already undergone imputation, which we 
carried through to this meta-analysis. We had to impute SNPs for the trio samples before the meta-analysis. As 
 
of this writing, and to the best of our knowledge, none of the imputation programs handle trios and supply 
posterior probabilities of the offspring's transmitted and non-transmitted alleles at each imputed locus. To 
resolve this, we phased the trios using Beagle, which outputs the most likely haplotypes for each parent split by 
transmitted and nontransmitted haplotypes. We then created case pseudo-control individuals consistent with the 
Haplotype Relative Risk (HRR) test.25,26 We then passed these case and pseudo-controls through Beagle 
27,28 to conduct imputation and analyzed the samples using MACH2DAT,29 using a logistic regression model. 
The p value from this analysis was then transformed into a z-score. The p value represents the probability of 
observing a test statistic equally or more deviant than the observed test statistic from the analysis. By the same 
token, we can consider the normal distribution and identify the critical value for which the ratio of the area under 
the normal distribution above the critical value plus the area under the normal distribution below the negative 
critical value to the total area under the normal distribution is equal to the p value. Considered another way, we 
are aiming to identify the z-score that is as deviant as the test statistic from the regression analysis. Conditional 
on this transformation we can then conduct meta-analysis of z-scores, which is described by de Bakker et al.30 




To conduct the meta-analysis, we first calculated the computed an association z-score corresponding to the 
association test statistic for each sample and then combined z's after weighting each by the inverse of the 
variances of the estimate of the odds ratios from each analysis. We then calculated the p value from this z-
score. Formula 1 shows the analytic method: 
  
where wi is the weight of each individual study, as defined by the variance of the estimate from the logistic 
regression, wt is the sum of these weights, and Zi is the z-score for each study, as defined by the p value and 
direction. 
 
Regional Association Plotting 
  
We highlight the most significant regions from the meta-analysis by use of the SNP annotation and Proxy 
(SNAP) Search website.31 SNAP displays and annotates association results, such that the LD patterns of the 





Genome-Wide Results   
The full distribution of results can be seen in the QQ plot in Figure 1. Under the null hypothesis of no 
association, these points should fall along the diagonal line. The dotted line plots the 95% confidence interval. 
The QQ plot and the lambda statistic (1.025) show no appreciable inflation of the test statistic. The lambdas 
for each individual study are 1.085 for IMAGE II, 1.012 for IMAGE, 0.970 for PUWMa, and 1.047 for CHOP, 
which yields an expected lambda of 1.028 based on the average lambda, weighted by case size. The lambda 
statistic is the ratio of the observed median chi-square test statistic to the theoretical expectation of the 
median chi-square.32 This approach capitalizes on the observation that an increase in the variance of the 
distribution of the test statistic will increase the median of the chi-square. This increase in variance can be 
caused by population stratification, technical bias, or other confounders. The reason that stratification can 
yield lambda is that the null conditions that the allele frequencies in cases and controls are the same are 
violated, and thus the test statistic is expected to increase. This slightly lower than expected lambda from the 
meta-analysis is indicative of no particular correlated bias across these studies, enhancing our confidence in 
the quality of results. These results show that our quality control procedures removed most association 
signals that could be attributed to either technical artifacts or population stratification, and that there is little 
evidence for correlated biases across the studies, as correlated biases will yield a further inflation of lambda. 
 
 
FIGURE 1 Quantile– quantile (QQ) plot of the metaanalysis of four attention-deficit/hyperactivity disorder genome-
wide associations studies. Note: The QQ plot shows the distribution of expected p-values based against observer 
distribution. There is slight inflammation in the distribution of results, as indicated by the lambda of 1.025. The red 
dashed line represents the 95% confidence interval for the distribution of results. 
 
Table 2 presents the top 50 findings of the meta-analysis. None of our results achieved genome-wide 
significance, defined as a p value of 5 × 10
-8
.33,34 We present the regional association plots for our top three 
findings across the meta-analysis, using SNAP 31 in Figures 2a, 2b, and 2c. Our top hit is rs1464807 (p = 1.10E-
06), which is in a gene-poor region. The SNP lies 230 kb 5' to SHFM1. The product of this gene may be involved 
in proteolysis and the regulation of the cell cycle. According to the NCBI Entrez Gene database 
(http://www.ncbi.nlm.nih.gov/gene/), mutations in the product of SHFM1 cause split hand/foot malformation type I. 
Eight SNPs in the region were among the top 50 findings in Table 2, which lends credibility to this association 
finding. Our second hit, rs177290098 (p = 1.68E-06), located in an intergenic region on chromosome 20, appears 
to be a false-positive result, as it is sufficiently poorly imputed in the three trio samples to be filtered from inclusion 
in the meta-analysis (Table 1) and SNPs in the region, which are in linkage disequilibrium (LD) with this SNP, do 
not show any association signal (Figure 2b). Given the low levels of recombination around this SNP, these 
surrounding SNPs are more likely to be reflective of the true association evidence in this region rather than the 
single large association observed. The third best hit, rs7463256, shows strong regional association, indicating that 
this is not likely to be a technical artifact. This association signal is close to the 5' end of the CHMP7 gene, with a 
number of additional SNPs in the top 50 list present located within the gene. CHMP7 is involved in the endosomal 
sorting pathway. Another three genes are present within 100 kb in this gene-rich area: TNFRSF10D, which 
protects against apoptosis; TNFRSF10A, which transduces cell death signals to start apoptosis; and LOXL2, 
which is involved in the biogenesis of connective tissue. 
TABLE 2 Top 50 Hits from The Genome-Wide Attention-Deficit/Hyperactivity Disorder (ADHD) Meta-Analysis 
 
  
FIGURE 2 Three region association plots are shown here. Note: On the x-axis is the base pair position based on 
the human genome 18 build. On the left y axis, the _log10(P-value) is reported. On the right y-axis, the 
recombination rate in cM per Mb is shown. The points are each individual single-nucleotide polymorphism (SNP), 
genotyped and imputed, color-coded by r2 to the most significant SNP in each region with dark red indicating an 
r2 between 0.8 and1 (high linkage disequilibrium [LD]), light red indicating an r2 between 0.5 and 0.8 (moderate 
LD), light pink indicating an r2 between 0.2 and 0.5 (low LD), and white indicating an r2 between 0 and 0.2 (no 
LD). 
 
Candidate Region Results   
We also generated the distribution of results for a previously defined set of ADHD candidate genes selected by 
the IMAGE team 35: ADRA1A, ADRA1B, ADRA2A, ADRA2C, ADRB2, ADRBK2, ARRB1, BDNF, CDH13, 
CHRNA4, COMT, CSNK1E, DBH, DDC, DRD1, DRD2, DRD3, DRD4, FADS1, FADS2, HES1, HTR1B, HTR1E, 
HTR2A, HTR2C, HTR3B, MAOA, MAOB, NFIL3, NR4A2, PER1, PER2, SLC18A2, SLC6A1, SLC6A2, SLC6A3, 
SLC6A4, SLC9A9, SNAP25, STX1A, SYT1, TPH1, and TPH2. These results from the 2752 SNPs in these 
candidate genes can be seen in Figure 3. The marked deviation of this SNP set from the null expectation 
(diagonal line) suggests that some of these variants are associated with ADHD, although none achieve genome-
wide significance. Finally, we present the top 50 results from the candidate gene SNPs in Table 3. 
 
 
FIGURE 3 Quantile– quantile (QQ) plot of candidate genes. Note: The QQ plot shows the distribution of expected 
p values against the observed distribution. The red dashed line represents the 95% confidence interval for the 



















We have presented the first meta-analysis of genome-wide association datasets for childhood ADHD, including 
a total of 2,064 trios, 896 cases, and 2,455 controls. Genome-wide significant effects still elude detection for this 
disorder, suggesting that the effect sizes for the common variants influencing risk for ADHD are likely to be very 
small. However, these results include a number of promising regions, for which replication is an essential next 
step. Moreover, our analysis of candidate genes suggests that some of these loci are worth studying further. 
  
The most strongly implicated region is on chromosome 7, where eight SNPs feature among the top 50 
association findings. The chromosome 7 region is gene-poor. The gene most near to the findings is the SHFM1 
gene, which still more than 200 kb away from the association findings and is not an obvious candidate for 
ADHD. According to Entrez, the product of SHFM1 may be involved in proteolysis and the regulation of the cell 
  
cycle. Mutations in the gene cause split hand/foot malformation, indicating that it functions from an early time 
point in embryonic development. SHFM1 is also expressed in the brain, which points to a possibly yet unknown 
function for this gene in the context of ADHD. Genetic variation in the same region was previously found to be 
associated with major depressive disorder and bipolar disorder at p values of 10
-4
 in GWAS.29,36 In addition to 
the finding on chromosome 7, a region on chromosome 20 contains the second best hit in our study. It includes 
four other SNPs from the top 50 list. This region does not lie close to known genes, however. 
A region on chromosome 8, featuring five SNPs in the top list, also seems interesting. The genes in this region 
play a role in immunity and cardiovascular processes, but the CHMP7 gene, implicated most stringently by our 
findings, also shows expression in the brain and has a function in endosomal sorting and vesicular transport.28 
Mutations in a related gene, CHMP2B, led to frontotemporal dementia, disinhibition, and executive 
dysfunction.37 A second (small) region on chromosome 8 implicated through four association findings in the top 
50 does not contain any genes, but lies less than 100 kb 5' to C8ORF83, a gene of unknown function. 
  
In addition to those, a region on chromosome 11 contains 8 of the 50 top findings. This region contains the 5' 
ends of two genes, DHCR7 and NADSYN1. The former encodes 7-dehydrocholesterol reductase, and mutations 
in this gene cause Smith–Lemli–Opitz syndrome. In adults, the ubiquitously transcribed DHCR7 is most 
abundant in adrenal gland, liver, testis, and brain. NADSYN1 encodes nicotinamide adenine dinucleotide (NAD) 
synthase 1, which catalyzes the final step in the biosynthesis of NAD from nicotinic acid adenine dinucleotide 
(NaAD). NAD is a coenzyme in metabolic redox reactions, a precursor for several cell signaling molecules, and 
a substrate for protein posttranslational modifications. Replication efforts will be necessary to be certain that 
these putative associations are actually related to ADHD. 
  
Clearly, this sample still lacks power to be able to unequivocally identify genome-wide significant associations of 
common genetic variants (SNPs) with ADHD. There are a number of possible explanations for why this lack of 
power still persists. First, it may be that the true effect sizes of individual genetic variants for ADHD are 
extremely small, accounting for less than 0.51% of the variance. As such, our findings remain in line with other 
psychiatric phenotypes. Recent work on psychiatric phenotypes such as schizophrenia and bipolar disorder 
have identified bona fide associations, but the combined sample size required to do is two to three times as 
large as the results presented in this study. As a result, further genome-wide association studies and replication 
efforts are essential. We note that at similar sample sizes for schizophrenia and bipolar disorder, there likewise 
were no unequivocal associations. Essentially, this meta-analysis imposes a ceiling on the effect size for 
common variation in the sample. We have 98% power to detect an effect accounting for 0.5% of the variance of 
the phenotype. The power to detect is 48% when we decrease the effect size to 0.25% of the variance and 
drops to 2% power when we consider an effect size of 0.1% of the phenotypic variance explained. These power 
calculations are all conducted assuming an alpha level of 5e-8, consistent with the genome-wide significance 
threshold, and are based on the postcleaning sample size. 
  
Beyond the question of effect size, there are other possible explanations for our negative findings. Although 
each data collection site provided diagnoses of ADHD based on structured, systematic interviews, there may be 
variability in measurement across data collection sites. Such variability would induce additional phenotypic (and 
probably genotypic) heterogeneity. Alternatively, a similar problem would arise if differences in local referral 
patterns led to increased heterogeneity between the datasets. In addition, it may be that much of the genetic 
variation that predisposes to ADHD is extremely rare and deleterious, rather than common and conferring 
modest risk. A number of studies in other psychiatric disorders recently suggested that a significant (albeit 
undefined) proportion of cases may be caused by such rare variants, in this case copy number variants.38 A first 
study in ADHD by members of this group also pointed to a role of such rare variants in this disorder.15 We also 
note that we may lose power from incomplete tagging of the putative causal variation. The expected 
non/centrality parameter for an SNP in LD with a functional variant is equal to the product of the r 2 and the 
noncentrality parameter at the causal locus.39 Furthermore, a gene × environment interaction may also yield a 
reduction in power, as might a gene × gene interaction. Although much of our sample is drawn from populations 
of western European descent, there is likely a great deal of environmental variability between the countries of 
origin that are included in this study, in terms of diet, exposure to toxins, and so forth. This variation may interact 
and influence the genetic mechanisms that predispose to ADHD and, as a consequence, limit power to detect 
an association. In all likelihood, each of these possible explanations may partially contribute to the difficulty in 
finding ADHD susceptibility genes through GWAS. 
  
This work should be viewed in the context of some limitations. Although we have conducted the largest genetic 
study of ADHD to date, our sample size is still relatively small compared with successful GWAS of complex 
disorders. Because creating this large sample required a collaborative effort among many sites, differences in 
ascertainment approaches and clinical assessments could have added noise to our sample and reduced power. 
Moreover, although using repository controls is a cost-effective strategy, because our control sample was not 
screened for ADHD, our power was less than it would have been for a screened sample. 
  
In conclusion, we amassed a sizeable genome-wide association dataset for meta-analysis consisting of 2,960 
individual childhood ADHD cases plus parental or independent control samples. Such numbers are indicative of 
a strong commitment by the ADHD genetics community to share data and to collaborate in the identification of 
significant associations to gain biological insight. Additional collaborative efforts should return true associations 
that will start to unravel the complex biological underpinnings of ADHD. 
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